Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CING
- Price
- 4.14
- Stock movement up
- +0.09 (2.31%)
- Company name
- Cingulate Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 21.60M
- Ent value
- 13.10M
- Price/Sales
- -
- Price/Book
- 1.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -68.83%
- 3 year return
- -77.70%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CING does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 0.07 |
| EV to EBITDA | 0.04 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.79 |
| EV to Sales | -0.00 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.41M |
| EPS (TTM) | -1833.03 |
| FCF per share (TTM) | -8133.14 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -3.85B |
| Gross profit (TTM) | -6.49B |
| Operating income (TTM) | -6.57B |
| Net income (TTM) | -3.24B |
| EPS (TTM) | -1.83K |
| EPS (1y forward) | -2.09 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 168.60% |
| Operating margin (TTM) | 170.73% |
| Profit margin (TTM) | 84.10% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 10.04M |
| Net receivables | 2.25K |
| Total current assets | 11.34B |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 13.58M |
| Accounts payable | 906.22K |
| Short/Current long term debt | 234.17K |
| Total current liabilities | 1.54M |
| Total liabilities | 1.54M |
| Shareholder's equity | 12.04M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.37B |
| Capital expenditures (TTM) | 294.93K |
| Free cash flow (TTM) | -14.37B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -26897.36% |
| Return on Assets | -23842.13% |
| Return on Invested Capital | -26384.09% |
| Cash Return on Invested Capital | -117066.34% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.91 |
| Daily high | 4.16 |
| Daily low | 3.81 |
| Daily Volume | 130K |
| All-time high | 933.60 |
| 1y analyst estimate | 27.71 |
| Beta | -0.75 |
| EPS (TTM) | -1833.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CING | S&P500 | |
| Current price drop from All-time high | -99.57% | -1.46% |
| Highest price drop | -99.80% | -56.47% |
| Date of highest drop | 14 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -82.80% | -10.99% |
| Avg time to new high | 464 days | 12 days |
| Max time to new high | 928 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
21.60M
Marketcap category
Small-cap
Description
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page